trial

A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia

NCTId NCT01724476
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 200 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2017-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
200 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-12
Primary completion
2017-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
folate with B12

Sponsors

Massachusetts General HospitalLead Sponsor
Addis Ababa UniversityCollaborator
Amanuel Mental Hospital, Addis Ababa, EthiopiaCollaborator

Investigators

1
Gregory Fricchione, MDPrincipal Investigator

Sites

1 total
Addis Ababa, Ethiopia

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE4
Primary Completion Date
2017-03
Status
COMPLETED
relationships
The graph out of here
drug
folate with B12
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
Addis Ababa University
company
Amanuel Mental Hospital, Addis Ababa, Ethiopia
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gregory Fricchione, MD
person